$BMY

Christopher Boerner

Bristol Myers Squibb

Chair & CEO • Since 2023 • Health Care

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

60/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: $13.9B → $12.8B (−7.9% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): −$8.9B → $7.1B (+178.8% YoY) — fiscal 2025 vs fiscal 2024

How this score works · S&P 500 reputation leaderboard

Overview

Christopher Boerner is the chair & ceo of Bristol Myers Squibb since 2023. Bristol Myers Squibb is a Health Care company headquartered in New York City, New York, founded in 1887, and one of the 500 companies in the S&P 500 — every one of which is profiled on this site.

Leadership

Christopher holds the chief executive role at Bristol Myers Squibb with the title Chair & CEO — in post since 2023. This page is the concise leadership record for Bristol Myers Squibb in the S&P 500 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $BMY
Headquarters: New York City, New York
Founded: 1887
CEO since: 2023
Index: S&P 500 (#72 of 500)